CWM
BPMC

Compass Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Compass Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-750
Closed -$66.4K – 186
2025
Q1 		$66.4K Hold
750
– – 0.02% 217
2024
Q4 		$65.4K Hold
750
– – 0.02% 224
2024
Q3 		$69.4K Hold
750
– – 0.02% 226
2024
Q2 		$80.8K Hold
750
– – 0.02% 215
2024
Q1 		$71.1K Hold
750
– – 0.02% 220
2023
Q4 		$69.2K Buy
+750
New +$48.6K 0.02% 217

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Compass Wealth Management's BPMC Position: Q2 2025 in Review

Compass Wealth Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 750 shares — an estimated $66.4K sold.

Compass Wealth Management first reported a position in BPMC in Q4 2023 and held it in 6 quarters. The position peaked at $80.8K in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Compass Wealth Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Compass Wealth Management sold 750 Blueprint Medicines shares in Q2 2025, an estimated $66.4K.
  • Compass Wealth Management first reported a position in Blueprint Medicines in Q4 2023 and held it in 6 quarters.
  • Compass Wealth Management's Blueprint Medicines position peaked at $80.8K in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.